Intel Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

Earnings Per Share

9 Months Ended

Sep. 28, 2024


Note 4 :			Earnings (Loss) Per Share

We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period.


	Three Months Ended				Nine Months Ended
(In Millions, Except Per Share Amounts)	Sep 28, 2024		Sep 30, 2023		Sep 28, 2024		Sep 30, 2023
Net income (loss)	$	(16,989)	$	310	$	(19,080)	$	(985)
Less: net income (loss) attributable to non-controlling interests	(350)		13		(450)		(5)
Net income (loss) attributable to Intel	$	(16,639)	$	297	$	(18,630)	$	(980)
Weighted average shares of common stock outstanding—basic	4,292		4,202		4,267		4,180
Dilutive effect of employee equity incentive plans	—		27		—		—

Weighted average shares of common stock outstanding—diluted	4,292		4,229		4,267		4,180
Earnings (loss) per share attributable to Intel—basic	$	(3.88)	$	0.07	$	(4.37)	$	(0.23)
Earnings (loss) per share attributable to Intel—diluted	$	(3.88)	$	0.07	$	(4.37)	$	(0.23)

Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. The potentially dilutive impact from the assumed issuance of common stock associated with the contractual conversion feature is determined by applying the if-converted method to the assumed exercise of the outstanding conversion feature.

In the three and nine months ended September 28, 2024 and in the nine months ended September 30, 2023, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, the assumed issuance of common stock under the stock purchase plan, and the assumed issuance of common stock associated with a contractual conversion feature, as applicable, had an anti-dilutive effect on diluted loss per share and were excluded from the computation of diluted loss per share. During the three months ended September 28, 2024, 160 million anti-dilutive shares were excluded from the computation of diluted earnings per share. In all other periods presented, securities that would have been anti-dilutive were insignificant.